<DOC>
	<DOCNO>NCT00669591</DOCNO>
	<brief_summary>The purpose study determine overall response combination bavituximab docetaxel patient advance breast cancer</brief_summary>
	<brief_title>A Safety Efficacy Study Bavituximab Plus Docetaxel Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult female age 18 life expectancy least 3 month Histologically cytologically confirm locally advance metastatic breast cancer One one prior chemotherapy regimen ( prior docetaxel ) Measurable disease ( least one target lesion ) least 2 cm long diameter ( 1 cm spiral CT ) Adequate hematologic , renal , hepatic function ; Known history bleed diathesis coagulopathy Any current evidence clinically significant bleed Any history thromboembolic event Concurrent hormone therapy Prior immunotherapy radiotherapy area measurable disease unless disease recur radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>docetaxel chemotherapy</keyword>
	<keyword>bavituximab</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>